Video Experimental Relacionado
Updated: Feb 8, 2026
07:52
Simultaneous EEG Monitoring During Transcranial Direct Current Stimulation
Published on: June 17, 2013
40.4K
Estudios clínicos actuales y en curso
Agessandro Abrahao1, Lorne Zinman1, Stephen Apple2
1Division of Neurology, Department of Medicine and Harquail Centre for Neuromodulation, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
Muscle & nerve
|February 7, 2026
Resumen
Ongoing studies evaluate edaravone (intravenous and oral suspension) for amyotrophic lateral sclerosis (ALS) treatment. Research aims to clarify efficacy, safety, and biological impact, supporting edaravone as a key ALS therapy option.
Área de la Ciencia:
- Neurología
- Farmacología
- Investigación Clínica
Sus antecedentes:
- La esclerosis lateral amiotrófica (ELA) es una enfermedad neurodegenerativa progresiva con opciones de tratamiento limitadas.
- La edaravona, disponible como suspensión intravenosa (IV) y oral, es un agente terapéutico emergente para la ELA.
- Comprender la utilidad clínica completa de la edaravona requiere una evaluación continua en diversos entornos de estudio.
Objetivo del estudio:
- Proporcionar una visión general completa de los estudios actuales y planificados sobre la edaravona para el tratamiento de la ELA.
- Evaluar la eficacia, seguridad y mecanismos biológicos de la edaravona en diversos contextos clínicos.
- Informar sobre las estrategias de tratamiento óptimas y los enfoques terapéuticos futuros para la ELA.
Principales métodos:
- Revisión de ensayos clínicos y estudios observacionales en curso y completados.
- Análisis de datos de la vigilancia postcomercialización y registros de historia natural.
- Inclusión de datos de biomarcadores para explorar el impacto fisiopatológico de la edaravona.
Principales resultados:
- Múltiples estudios están evaluando tanto la edaravona intravenosa como la suspensión oral de edaravona.
- La investigación en curso incluye vigilancia a largo plazo, seguimiento de la historia natural y análisis de biomarcadores.
- Los ensayos clínicos han respaldado la seguridad, tolerabilidad y eficacia de las formulaciones de edaravona.
Conclusiones:
- Los estudios actuales y en curso respaldan colectivamente la edaravona como una valiosa opción terapéutica para la ELA.
- La recopilación continua de datos de ensayos clínicos y de la práctica es crucial para refinar el tratamiento con edaravona.
- Estos esfuerzos guiarán las estrategias óptimas y las terapias combinadas en el panorama cambiante de la ELA.
Videos de Conceptos Relacionados
01:21Aneurysm II: Clinical Manifestations and Diagnostic Studies
371
Thoracic, aortic arch and abdominal aneurysms are significant vascular conditions that can present with various clinical manifestations and lead to serious complications. Understanding these manifestations and the appropriate diagnostic studies is essential for effective management and treatment.Thoracic Aortic AneurysmsThoracic aortic aneurysms often remain asymptomatic until they reach a size that impinges on adjacent structures. They typically cause deep, diffuse chest pain that radiates to...
371
01:30Hypertension III: Clinical Manifestations and Diagnostic Studies
585
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
585
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
349
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
349
01:10Electrical Current
7.2K
Electrical current is defined as the rate at which charge flows. When there is a large current present, such as that used to run a refrigerator, a large amount of charge moves through the wire in a small amount of time. If the current is small, such as that used to operate a handheld calculator, a small amount of charge moves through the circuit over a long period of time. The SI unit for current is the ampere (A), named for the French physicist André-Marie Ampère (1775–1836).
7.2K
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
635
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
635
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
614
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
614